- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05359211
NKTR-255 i kombination med CAR-T-cellterapi för behandling av återfallande eller refraktärt stort B-cellslymfom
En öppen fas Ib-studie som utvärderar säkerheten och effekten av NKTR-255 i kombination med CD19-riktad CAR-T-cellterapi hos patienter med återfall/refraktärt (R/R) stort B-cellslymfom (LBCL)
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone.
Studieöversikt
Status
Betingelser
- Återkommande diffust stort B-cellslymfom
- Refraktärt diffust stort B-cellslymfom
- Återkommande diffust stort B-cellslymfom, ej specificerat på annat sätt
- Refraktärt diffust stort B-cellslymfom, ej specificerat på annat sätt
- Återkommande follikulärt lymfom grad 3b
- Refraktär grad 3b follikulärt lymfom
- Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort B-cellslymfom
- Återkommande primärt mediastinalt stort B-cellslymfom
- Refraktärt primärt mediastinalt stort B-cellslymfom
Intervention / Behandling
- Läkemedel: Cyclophosphamide
- Procedur: Multigated Acquisition Scan
- Procedur: X-Ray Imaging
- Procedur: Positron Emission Tomography
- Procedur: Bone Marrow Aspiration
- Procedur: Bone Marrow Biopsy
- Läkemedel: Fludarabine
- Procedur: Echocardiography
- Procedur: Computed Tomography
- Biologisk: Lisocabtagene Maraleucel
- Läkemedel: Polymer-conjugated IL-15 Receptor Agonist NKTR-255
- Procedur: Lumbar Puncture
- Procedur: Biospecimen Collection
- Procedur: Biopsy
Detaljerad beskrivning
OUTLINE:
Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 intravenously (IV) over 30 minutes every 3 weeks starting on day 10 or 14 in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients undergo bone marrow biopsy and aspiration, lumbar puncture (LP) for cerebrospinal fluid (CSF) sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo positron emission tomography (PET)/computed tomography (CT) throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.
After completion of study treatment, patients are followed up every 30 days then every 3 months up to 12 months after the CAR-T cell infusion.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female >= 18 years of age at the time of consent
- Patients with LBCL (including diffuse large B-cell lymphoma [DLBCL] not otherwise specified [including DLBCL arising from indolent lymphoma], high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B) with a Food and Drug Administration (FDA)-approved indication for treatment with liso-cel
- Fludeoxyglucose F-18 (FDG)-avid disease on positron emission tomography (PET) imaging or pathology evidence of active disease
- Evidence of CD19 expression on any prior or current tumor specimen or a high likelihood of CD19 expression based on disease histology
- Karnofsky performance status >= 60%
- Absolute neutrophil count (ANC) >= 1000 cells/mm^3 in the absence of bone marrow involvement by lymphoma
- Platelets >= 50,000 cells/mm^3 in the absence of bone marrow involvement by lymphoma
- Hemoglobin >= 8 g/dL in the absence of bone marrow involvement by lymphoma
- Calculated creatinine clearance (Cockcroft/Gault) > 30 mL/min/1.73 m^2
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (or < 5 x ULN for subjects with lymphomatous infiltration of the liver)
- Total bilirubin =< 2 (or < 3.0 for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
- Common Terminology Criteria for Adverse Events (CTCAE) Grade =< 1 dyspnea
- Saturation of oxygen (Sa02) >= 92% on room air
- Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a forced expiratory volume in 1 second (FEV1) of >= 50% of predicted value
- Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a diffusing capacity of the lung for carbon monoxide (DLCO; corrected) >= 40% of predicted value
- Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA)
- Patients with Fridericia's corrected QT interval (QTcF) > 450 ms for men and > 470 ms for women will require clearance by a cardiologist
- Women of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for 1 month after the last dose of study therapy (NKTR-255)
- Males who have partners of reproductive potential must agree to use an effective barrier contraceptive method for 1 month after the last dose of study therapy (NKTR-255)
- Ability to understand and provide informed consent
- Able and willing to comply with study visit schedule and procedures, including tumor biopsy where feasible and with acceptable risk
Exclusion Criteria:
-
Planned use of therapeutic doses of corticosteroids (> 20 mg/day prednisone or equivalent) or other systemic immunosuppression within 7 days prior to leukapheresis or within 72 hours prior to liso-cel infusion. Topical and/or inhaled steroids are permitted
-
Prior treatment with any CD19 CAR-T cell therapy
-
For allogeneic hematopoietic cell transplant (HCT) recipients, active graft versus host disease (GVHD) and/or systemic GVHD therapy within 30 days prior to planned leukapheresis
-
Known active hepatitis B (detectable hepatitis B deoxyribonucleic acid [DNA]) or hepatitis C (detectable hepatitis C ribonucleic acid [RNA])
-
Known human immunodeficiency virus (HIV) infection
-
Pregnant or breastfeeding women
-
Prior treatment with any IL-2 or IL-15 agonist and/or biosimilar agents
-
Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., ulcerative colitis, Crohn's disease], celiac disease, or other serious chronic gastrointestinal conditions associated with diarrhea, autoimmune vasculitis, systemic lupus erythematosus, Wegener syndrome [granulomatosis with polyangiitis], myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.) requiring immunosuppressive therapy. The following are exceptions to this criterion:
- Vitiligo.
- Alopecia.
- Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
- Type 1 diabetes mellitus.
- Psoriasis not requiring systemic treatment.
- Conditions considered to be low risk of serious deterioration by the principal investigator (PI).
-
History of any one of the following cardiovascular conditions within the past 6 months: class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, or unstable angina; unless clearance by a cardiologist is obtained. History of other clinically significant cardiac disease that, in the opinion of the PI or designee, is a contraindication to study treatment is also excluded
-
History or presence of clinically relevant central nervous system (CNS) pathology, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or psychosis that in the opinion of the PI is a contraindication to study treatment.
- Patients with active parenchymal CNS involvement by malignancy will be excluded. Patients with prior or current secondary leptomeningeal CNS disease are eligible. CNS disease prophylaxis must be stopped at least 1 week prior to liso-cel infusion
-
History of solid organ transplantation
-
Active, serious, and uncontrolled infection(s)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (lymphodepletion, liso-cel, NKTR-255)
Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and ECHO or MUGA during screening. Patients undergo bone marrow biopsy and aspiration, LP for CSF sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo PET/CT throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial. |
Given IV
Andra namn:
Undergo MUGA
Andra namn:
Undergo x-ray imaging
Andra namn:
Undergo PET/CT
Andra namn:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andra namn:
Given IV
Andra namn:
Undergo ECHO
Andra namn:
Undergo PET/CT
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo LP
Andra namn:
Undergo blood and CSF sample collection
Andra namn:
Undergo tissue biopsy
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of adverse events (AEs)
Tidsram: 30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated
|
Grade ≥ 3 AEs considered related to NKTR-255 will be listed and summarized. Summaries of grade ≥ 3 laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the safety evaluable population. |
30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated
|
|
Dose-limiting toxicity (DLT) rates
Tidsram: Up to 21 days after the first NKTR-255 infusion
|
Observed DLT rates will be summarized based on the DLT evaluable population. Final DLT rates at each dose level will be estimated by isotonic regression by applying the pooled adjacent violators algorithm. |
Up to 21 days after the first NKTR-255 infusion
|
|
Optimal biological dose (OBD)
Tidsram: Up to 12 months after the CAR-T cell infusion
|
A composite of clinical information will be utilized to determine the OBD based on safety and tolerability, confirmation of maximum target engagement, optimal biological effects without undesirable clinical effects, pharmacokinetic parameters, and biological response data. |
Up to 12 months after the CAR-T cell infusion
|
|
Complete response (CR) rate
Tidsram: Up to 3 months after the CAR-T cell infusion
|
The CR rate will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence interval based on the efficacy evaluable population. |
Up to 3 months after the CAR-T cell infusion
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Complete response (CR) and overall response (OR) rates
Tidsram: Up to 12 months after the CAR-T cell infusion
|
The CR and OR rates will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence interval based on the efficacy evaluable population. |
Up to 12 months after the CAR-T cell infusion
|
|
Duration of response (DOR)
Tidsram: Up to 12 months after the CAR-T cell infusion
|
Will be assessed among responders. If a patient does not have an event for the DOR analyses, the patient will be censored at the date of the last adequate disease assessments or prior to the earliest censoring event. The censoring reason can include last contact/follow-up, discontinuation or completion of the study, receipt of another anticancer treatment with the exception of consolidation therapy with hematopoietic cell transplantation (HCT), and at least two consecutive missed scheduled disease assessments. Kaplan-Meier (KM) method will be used to analyze DOR. |
Up to 12 months after the CAR-T cell infusion
|
|
Progression free survival (PFS)
Tidsram: Up to 12 months after the CAR-T cell infusion
|
Will be assessed among responders. If a patient does not have an event for the PFS analyses, the patient will be censored at the date of the last adequate disease assessments or prior to the earliest censoring event. The censoring reason can include last contact/follow-up, discontinuation or completion of the study, receipt of another anticancer treatment with the exception of consolidation therapy with HCT, and at least two consecutive missed scheduled disease assessments. KM method will be used to analyze PFS. |
Up to 12 months after the CAR-T cell infusion
|
|
Overall survival (OS)
Tidsram: Up to 12 months after the CAR-T cell infusion
|
Analyses of OS will be performed in the safety population. For assessment of OS, data from surviving patients will be censored at the last time that the patient is known to be alive. KM method will be used to analyze OS. |
Up to 12 months after the CAR-T cell infusion
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Alexandre Hirayama, Fred Hutch/University of Washington Cancer Consortium
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Lymfom, icke-Hodgkin
- Lymfom, B-cell
- Lymfom
- Hemiska och lymfsjukdomar
- Lymfom, stor B-cell, diffus
- Organiska kemikalier
- Undersökningstekniker
- Terapeutik
- Provhantering
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Punktering
- Kirurgiska ingrepp, operativ
- Cytologiska tekniker
- Cytodiagnos
- Kolväten
- Fysiska fenomen
- Utrustning och förnödenheter
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Elektromagnetiska fenomen
- Magnetfenomen
- Diagnostiska tekniker, neurologiska
- Elektromagnetisk strålning
- Strålning
- Strålning, joniserande
- Cyklofosfamid
- Biopsi
- Magnetresonansspektroskopi
- fludarabin
- Ryggpunkter
- Röntgenstrålar
- Fantom, avbildning
- NKTR-255
Andra studie-ID-nummer
- RG1122036
- NCI-2022-02316 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- 10802 (Annan identifierare: Fred Hutch/University of Washington Cancer Consortium)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .